PolyPid Ltd. (NASDAQ:PYPD) Sees Large Increase in Short Interest

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 447,180 shares, a growth of 98.3% from the October 15th total of 225,458 shares. Based on an average daily volume of 128,450 shares, the short-interest ratio is presently 3.5 days. Approximately 3.1% of the shares of the company are short sold.

Analyst Ratings Changes

Several analysts recently weighed in on PYPD shares. Oppenheimer assumed coverage on PolyPid in a research note on Tuesday, October 27th. They set an “outperform” rating and a $10.00 target price for the company. Craig Hallum set a $12.00 target price on shares of PolyPid in a research report on Wednesday, July 22nd. Wall Street Zen cut shares of PolyPid from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of PolyPid in a research report on Thursday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Read Our Latest Report on PYPD

PolyPid Price Performance

Shares of PYPD traded down $0.11 on Monday, reaching $6.15. 211,750 shares of the stock traded hands, compared to its average volume of 127,244. The firm has a market cap of $117.36 million, a price-to-earnings ratio of -4.56 and a beta of 1.43. PolyPid has a 12 month low of $3.50 and a 12 month high of $7.15. The stock’s 50-day moving average price is $5.37 and its 200-day moving average price is $4.80.

PolyPid (NASDAQ:PYPD – Get Free Report) last announced its quarterly earnings results on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by ($1.15). The business had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $30.00 million. As a group, equities research analysts forecast that PolyPid will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. HighTower Advisors LLC bought a new position in PolyPid during the second quarter worth about $56,000. AXQ Capital LP bought a new stake in shares of PolyPid in the 2nd quarter valued at approximately $87,000. Renaissance Technologies LLC bought a new stake in shares of PolyPid in the 1st quarter valued at approximately $81,000. B. Riley Wealth Advisors Inc. raised its holdings in shares of PolyPid by 32.7% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock worth $106,000 after buying an additional 4,955 shares in the last quarter. Finally, Connective Capital Management LLC acquired a new position in shares of PolyPid in the 2nd quarter worth approximately $343,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Company Profile

(Get Free Report)

PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.

See Also

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.